Showing results (251-260 of 494) with videos related to

Sort By:
Pageof 50
BMC Cancer|December 1, 2009
Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expressionJerzy Ostrowski, Marcin Polkowski, Agnieszka Paziewska, et al.
Cell|May 28, 2019
A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and LeukemiaNinib Baryawno, Dariusz Przybylski, Monika S Kowalczyk, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2021
Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical TrialMateusz J Spałek, Hanna Koseła-Paterczyk, Aneta Borkowska, et al.
American Journal of Therapeutics|June 11, 2014
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countriesAlberto Wainstein, Salvador Martin Algarra, Lars Bastholt, et al.
Melanoma Research|February 20, 2020
The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanomaArtur Kowalik, Monika Jurkowska, Ewa Mierzejewska, et al.
Melanoma Research|March 30, 2020
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanomaBożena Cybulska-Stopa, Paweł Rogala, Anna M Czarnecka, et al.
Cancers|June 27, 2019
Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAsAzadeh Amirnasr, Caroline M M Gits, Patricia F van Kuijk, et al.
Seminars in Oncology|August 12, 2009
Other targetable sarcomasVeridiana Pires de Camargo, Matt van de Rijn, Roberta Maestro, et al.
JAMA Network Open|February 17, 2026
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical TrialSancy A Leachman, Jason J Luke, Paolo A Ascierto, et al.
Cancer Immunology, Immunotherapy : CII|June 18, 2026
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignanciesPiotr Rutkowski, Dariusz M Kowalski, Victor Moreno, et al.
Pageof 50